Is Artemis Medicare overvalued or undervalued?

As of 1 October 2025, the valuation grade for Artemis Medicare has moved from attractive to very attractive, indicating a significant positive shift in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 37.38, an EV to EBITDA of 20.10, and a PEG ratio of 0.70, which suggests that the stock may be priced favorably relative to its growth potential.
In comparison to its peers, Artemis Medicare's valuation stands out; for instance, Max Healthcare has a PE ratio of 89.97 and Apollo Hospitals has a PE ratio of 68.03, both of which are considerably higher. This reinforces the notion that Artemis Medicare is undervalued in its sector. Additionally, despite a recent decline in stock performance relative to the Sensex over the year, the long-term returns of 283.27% over three years and 1404.81% over five years highlight its strong growth potential, further supporting the undervaluation thesis.